dc.contributor.author | Sharma, G | |
dc.contributor.author | Braga, MC | |
dc.contributor.author | Da Pieve, C | |
dc.contributor.author | Szopa, W | |
dc.contributor.author | Starzetz, T | |
dc.contributor.author | Plate, KH | |
dc.contributor.author | Kaspera, W | |
dc.contributor.author | Kramer-Marek, G | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2023-09-06T08:54:42Z | |
dc.date.available | 2023-09-06T08:54:42Z | |
dc.date.issued | 2023-06-09 | |
dc.identifier | ARTN 3131 | |
dc.identifier | cancers15123131 | |
dc.identifier.citation | Cancers, 2023, 15 (12), pp. 3131 - | en_US |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5956 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.doi | 10.3390/cancers15123131 | |
dc.description.abstract | There is no established method to assess the PD-L1 expression in brain tumours. Therefore, we investigated the suitability of affibody molecule (ZPD-L1) radiolabelled with F-18 (Al18F) and Ga-68 to measure the expression of PD-L1 in xenograft mouse models of GBM. Mice bearing subcutaneous and orthotopic tumours were imaged 1 h post-radioconjugate administration. Ex vivo biodistribution studies and immunohistochemistry (IHC) staining were performed. Tumoural PD-L1 expression and CD4+/CD8+ tumour-infiltrating lymphocytes were evaluated in human GBM specimens. ZPD-L1 was radiolabelled with radiochemical yields of 32.2 ± 4.4% (F-18) and 73.3 ± 1.8% (Ga-68). The cell-associated radioactivity in vitro was consistent with PD-L1 expression levels assessed with flow cytometry. In vivo imaging demonstrated that 18F-AlF-NOTA-ZPD-L1 can distinguish between PD-L1 high-expressing tumours (U87-MGvIII) and PD-L1-negative ones (H292PD-L1Ko). The radioconjugate was quickly cleared from the blood and normal tissues, allowing for high-contrast images of brain tumours as early as 1 h post-injection. 68Ga-NOTA-ZPD-L1 showed heterogeneous and diffuse accumulation that corresponded to the extensively infiltrating GCGR-E55 tumours involving contiguous lobes of the brain. Lastly, 39% of analysed GBM patient samples showed PD-L1+ staining of tumour cells that was associated with elevated levels of CD4+ and CD8+ lymphocytes. Our results suggest that the investigated radioconjugates are very promising agents with the potential to facilitate the future design of treatment regimens for GBM patients. | |
dc.format | Electronic | |
dc.format.extent | 3131 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.relation.ispartof | Cancers | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | PD-L1 | |
dc.subject | affibody molecule | |
dc.subject | glioblastoma | |
dc.subject | immuno-PET | |
dc.title | Immuno-PET Imaging of Tumour PD-L1 Expression in Glioblastoma. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-06-08 | |
dc.date.updated | 2023-09-06T08:53:24Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.3390/cancers15123131 | en_US |
rioxxterms.licenseref.startdate | 2023-06-09 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37370741 | |
pubs.issue | 12 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.3390/cancers15123131 | |
pubs.volume | 15 | |
icr.researchteam | Preclin Molecular Imaging | en_US |
dc.contributor.icrauthor | Da Pieve, Chiara | |
dc.contributor.icrauthor | Kramer-Marek, Gabriela | |
icr.provenance | Deposited by Mr Arek Surman on 2023-09-06. Deposit type is initial. No. of files: 1. Files: Immuno-PET Imaging of Tumour PD-L1 Expression in Glioblastoma.pdf | |